BAUSCH + LOMB CORP (BLCO)

CA0717051076 - Common Stock

20  0 (0%)

After market: 20 0 (0%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

BAUSCH + LOMB CORP

NYSE:BLCO (9/19/2024, 6:40:01 PM)

After market: 20 0 (0%)

20

0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month23.69%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap7.04B
Shares
PE30.3
Fwd PE22.89
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

BLCO Daily chart

Company Profile

Bausch + Lomb Corp. develops, manufactures, and markets eye health products. The company is headquartered in Vaughan, Ontario and currently employs 13,300 full-time employees. The company went IPO on 2022-05-06. The company operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. The Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. The Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.

Company Info

BAUSCH + LOMB CORP

520 Applewood Crescent

Vaughan ONTARIO

P: 19082552864

Employees: 13300

Website: https://ir.bausch.com/

BLCO News

News Image2 days ago - BloombergBausch Health Taps Jefferies to Refinance Debt, Aid Spinoff

Bausch Health Cos. is working with Jefferies Financial Group to explore refinancing some of its debt to aid a long-planned spinoff of its stake in the eye-care company Bausch + Lomb, according to people with knowledge of the situation.

News Image3 days ago - The Motley FoolWhy Bausch + Lomb Rallied Today

The highly indebted healthcare stock rose on rumors it may be selling itself.

News Image3 days ago - Investor's Business DailyBausch Reportedly Explores A Sale; Could Alcon, J&J Or AbbVie Buy It?

Bausch + Lomb is reportedly considering a sale. But its potential acquirers could come up against antitrust concerns.

ChartMill News Image3 days ago - ChartmillThe market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session.

Gapping stocks in Monday's session

News Image3 days ago - BloombergBausch + Lomb Soars on Report That It’s Exploring a Sale

Bausch + Lomb Corp. shares rose the most ever following a report that the eye-care company is considering selling itself to disentangle from its debt-laden parent company.

News Imagea month ago - Market News VideoThursday 8/8 Insider Buying Report: NINE, BLCO

BLCO Twits

Here you can normally see the latest stock twits on BLCO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example